Stuart Mair

535 total citations
27 papers, 415 citations indexed

About

Stuart Mair is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Stuart Mair has authored 27 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Immunology and 6 papers in Epidemiology. Recurrent topics in Stuart Mair's work include Biosimilars and Bioanalytical Methods (4 papers), Neutropenia and Cancer Infections (3 papers) and Diabetes Treatment and Management (3 papers). Stuart Mair is often cited by papers focused on Biosimilars and Bioanalytical Methods (4 papers), Neutropenia and Cancer Infections (3 papers) and Diabetes Treatment and Management (3 papers). Stuart Mair collaborates with scholars based in United Kingdom, United States and Spain. Stuart Mair's co-authors include Miguel H. Bronchud, Cornelius F. Waller, Lloyd Stevens, Giorgia Rossi, Ian C. T. Nisbet, Shampa Das, Claudio Giuliano, James Atherton, Anshul Gupta and Timi Edeki and has published in prestigious journals such as Blood, Annals of Oncology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Stuart Mair

25 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart Mair United Kingdom	13	114	107	89	81	67	27	415
Hyewon Chung South Korea	16	64 0.6×	50 0.5×	128 1.4×	69 0.9×	65 1.0×	45	592
Claudia P. Schroeder United States	12	57 0.5×	62 0.6×	142 1.6×	38 0.5×	29 0.4×	39	360
Qianzhou Lv China	13	54 0.5×	75 0.7×	112 1.3×	40 0.5×	46 0.7×	41	428
Ye Won Jeon South Korea	14	227 2.0×	46 0.4×	143 1.6×	123 1.5×	105 1.6×	36	566
Christine Hauser Australia	11	142 1.2×	102 1.0×	380 4.3×	58 0.7×	34 0.5×	22	756
Takayuki Tanabe Japan	10	55 0.5×	103 1.0×	157 1.8×	47 0.6×	24 0.4×	44	445
Marc E. De Broe Belgium	7	52 0.5×	71 0.7×	116 1.3×	61 0.8×	55 0.8×	9	367
Masayuki Ohbayashi Japan	14	297 2.6×	73 0.7×	224 2.5×	36 0.4×	22 0.3×	34	664
Daniel Bulut Germany	17	71 0.6×	55 0.5×	226 2.5×	116 1.4×	90 1.3×	27	682

Countries citing papers authored by Stuart Mair

Since Specialization

Citations

This map shows the geographic impact of Stuart Mair's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Mair with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Mair more than expected).

Fields of papers citing papers by Stuart Mair

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Mair. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Mair. The network helps show where Stuart Mair may publish in the future.

Co-authorship network of co-authors of Stuart Mair

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Mair. A scholar is included among the top collaborators of Stuart Mair based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Mair. Stuart Mair is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adams, Mary Beth, Anastasia Parton, Jamie N. Connarn, et al.. (2022). CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production. Arthritis Research & Therapy. 24(1). 199–199. 17 indexed citations

Albayaty, Muna, James Bush, Joseph Cheriyan, et al.. (2020). The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. Frontiers in Pharmacology. 11. 580560–580560.

Mathis, Amanda, Stuart Mair, Diane Gesty‐Palmer, et al.. (2020). BCX9930, an Oral Factor D Inhibitor, for the Potential Treatment of Alternative Pathway Mediated Diseases: Interim Results of a Phase 1 Study in Healthy Subjects. Blood. 136(Supplement 1). 15–16. 3 indexed citations

McDermott, John, et al.. (2019). Preparation, Pre-clinical and Clinical Evaluation of a Novel Rapidly Absorbed Celecoxib Formulation. AAPS PharmSciTech. 20(2). 90–90. 8 indexed citations

Blum, Robert A., Stuart Mair, & Elizabeth Manning Duus. (2019). Appetite and food intake results from phase I studies of anamorelin. Journal of Cachexia Sarcopenia and Muscle. 10(5). 1027–1035. 16 indexed citations

Mair, Stuart, et al.. (2018). Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials. Annals of Oncology. 29. viii608–viii609. 1 indexed citations

Reijntjes, Susan, Muna Albayaty, James Bush, et al.. (2018). The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. Frontiers in Pharmacology. 9. 1301–1301. 1 indexed citations

Hounslow, Neil, et al.. (2018). Pemafibrate Has High Bioavailability and is Principally Excreted via the Liver. Atherosclerosis Supplements. 32. 157–157. 13 indexed citations

Molnár, László, et al.. (2017). Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect. Cancer Chemotherapy and Pharmacology. 80(4). 723–728. 24 indexed citations

10.

Howes, Colin, et al.. (2016). Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects. Clinical Therapeutics. 38(11). 2447–2458. 24 indexed citations

11.

McEwen, Andrew, Laura Lawrence, Randy C. Hoover, et al.. (2015). Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration. Xenobiotica. 45(12). 1054–1062. 21 indexed citations

12.

Vishwanathan, Karthick, Stuart Mair, Anshul Gupta, et al.. (2014). Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential. Drug Metabolism and Disposition. 42(5). 932–942. 42 indexed citations

13.

Giuliano, Claudio, et al.. (2013). Netupitant PET imaging and ADME studies in humans. The Journal of Clinical Pharmacology. 54(1). 97–108. 47 indexed citations

14.

Mair, Stuart, et al.. (2013). Absorption, metabolism and excretion of [¹⁴C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Xenobiotica. 44(6). 522–530. 18 indexed citations

15.

Nakamaru, Yoshinobu, Yoshiharu Hayashi, Ruriko Ikegawa, et al.. (2013). Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica. 44(3). 242–253. 50 indexed citations

16.

Connor, Alyson, et al.. (2012). Design and implementation of a multi-part, flexible protocol to assess the tolerability and pharmacodynamic effects of PUR118 in healthy subjects and COPD patients. 40. 2155.

17.

Waller, Cornelius F., et al.. (2010). Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Annals of Hematology. 89(9). 927–933. 30 indexed citations

18.

Waller, Cornelius F., et al.. (2010). Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Annals of Hematology. 89(10). 971–978. 35 indexed citations

19.

Mair, Stuart, et al.. (2009). Immunogenicity and safety of PNEUMOVAX^®II manufactured by a new process in older adults. Human Vaccines. 5(9). 608–613. 3 indexed citations

20.

Rordorf, Christiane, Norma Kellett, Stuart Mair, et al.. (2003). Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Alimentary Pharmacology & Therapeutics. 18(5). 533–541. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact